A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings
Viruses · 14.12.2023 · 15 (12) · 2426
DOI: 10.3390/v15122426 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 14.12.2023. Verfasst von Cassidy Henegar und 7 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA. Hauptthemen laut MEDLINE: HIV Integrase Inhibitors, HIV Integrase, HIV Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV who experience virologic failure while on DTG-based regimens. We searched the PubMed, Embase, and Cochrane databases to identify studies that reported DTG resistance-associated mutations (RAMs) emerging under selection pressure. Our review showed that RAMs conferring resistance to DTG were rare in 2-drug and 3-drug regimens used in real-world cohorts, corroborating data from clinical trials. The potency of DTG in maintaining virologic suppression was demonstrated, even in cases of pre-existing resistance to companion drugs in the regimen. Estimates of DTG RAMs depended on the population and certain risk factors, including monotherapy, baseline resistance or lack of genotypic testing, treatment history and prior virologic failure, and suboptimal treatment adherence. The RAMs detected after virologic failure, often in heavily treatment-experienced individuals with prior exposure to integrase strand transfer inhibitors, were G118R, E138K, G140A/C/R/S, Q148H/K/R, N155H, and R263K. Overall, these data highlight the durable effectiveness and high barrier to resistance of DTG as part of combination antiretroviral therapy in a wide variety of settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
- ViiV Healthcare, P.T.M., Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain.
- ViiV Healthcare, 980 Great West Road, Brentford TW8 9GS, Middlesex, UK.
ORCID-Profile: Bryn Jones
Förderung
- ViiV Healthcare
Zitieren
APA
Henegar, C., Letang, E., Wang, R., Hicks, C., Fox, D., Jones, B., de Ruiter, A., & Vannappagari, V. (2023). A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings. Viruses, 15(12), 2426. https://doi.org/10.3390/v15122426
Vancouver
Henegar C, Letang E, Wang R, Hicks C, Fox D, Jones B, et al. A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings. Viruses. 2023;15(12):2426. doi:10.3390/v15122426
BibTeX
@article{Henegar2023,
author = {Henegar, Cassidy and Letang, Emilio and Wang, Ruolan and Hicks, Charles and Fox, Dainielle and Jones, Bryn and de Ruiter, Annemiek and Vannappagari, Vani},
title = {A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings},
journal = {Viruses},
year = {2023},
volume = {15},
number = {12},
pages = {2426},
doi = {10.3390/v15122426}
}
EUVIMED